Document

2nd Quarter 2022

YTD 2022

Revenue, increase

$240 million, 15%

$468 million, 16%

Revenue increase (organic)1

Earnings per diluted share

$0.29

$0.20

Adjusted earnings per diluted share

$0.60

$1.09

Cash flow from operating activities

$43 million

$42 million

Free cash flow before restructuring & restructuring related costs

$29 million

$31 million

1 Excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures.

Chris Simon, Haemonetics’ CEO, stated: “All of our businesses are building momentum with revenue increases. While we encountered a delay in the acceleration of plasma collections in the quarter, we did see encouraging signs of recovery and our Hospital and Blood Center businesses delivered strong sales despite the resurgence of COVID-19. We anticipate additional growth across in our Plasma and Hospital businesses in the second half of fiscal 22. Our teams continue to show strong resilience overcoming supply chain challenges and we are ready to support our customers as the pandemic recedes.”

Gross margin was 51.1% in the second quarter of fiscal 2022, compared with 50.5% in the second quarter of fiscal 2021. Operating expenses were $98.0 million in the second quarter of fiscal 2022, compared with $47.0 million in the same period in the prior year. The Company had operating income of $24.5 million and a 10.2% operating margin in the second quarter of fiscal 2022, compared with operating income of $58.8 million and an operating margin of 28.1% in second quarter of fiscal 2021. The income tax rates were 25% and 12% in the second quarters of fiscal 2022 and fiscal 2021, respectively. Second quarter fiscal 2022 net income and earnings per diluted share were $14.9 million and $0.29, respectively, compared with net income and earnings per diluted share of $48.1 million and $0.94, respectively, in the second quarter of fiscal 2021.

Second quarter fiscal 2022 adjusted gross margin was 52.6%, up 40 basis points compared with the same prior year period. The primary drivers of this improvement were the acquisition of our Vascular Closure business, productivity savings from the Operational Excellence Program and favorable product mix, partially offset by the impact of price adjustments as well as inflationary pressures in our global manufacturing and supply chain.

Adjusted operating expenses in the second quarter of fiscal 2022 were $82.4 million, up $16.0 million, or 24.1%, compared with the same prior year period. The increase in adjusted operating expenses was primarily driven by the acquisition of our Vascular Closure business and an increase in freight costs. Adjusted operating income for the second quarter of fiscal 2022 was $43.8 million, up $0.8 million or 2.0%, and adjusted operating margin was 18.3%, down 220 basis points compared with the second quarter of fiscal 2021. The adjusted income tax rate was 22% in the second quarter of fiscal 2022 compared with an adjusted income tax rate of 19% in the second quarter of fiscal 2021.


	Previous Organic1 Guidance	Current Organic1 Guidance
Total revenue	8 - 12%	7 - 10%
Plasma revenue	15 - 25%	10 - 20%
Hospital revenue	15 - 20%	15 - 20%
Blood Center revenue	(6 - 8%)	(3 - 5%)
1Excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. Reconciliations of reported to organic revenue are provided in the schedules accompanying this release and in the analytical tables referenced below.

The Company will host a conference call with investors and analysts to discuss second quarter fiscal 2022 results on Tuesday, November 9, 2021 at 8:00am EST. Interested parties may participate by telephone by dialing (877) 848-8880 from within the U.S. or Canada or (716) 335-9512 from international locations, using the access code 3529538. Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/apntfy73

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products and plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the impact of the COVID-19 pandemic on the Company’s operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current

projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the impact of the COVID-19 pandemic, including the scope and duration of the outbreak; government actions and restrictive measures implemented in response; availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; risks arising from the Company’s acquisition of Cardiva Medical Inc., including any failure to realize the anticipated benefits of the transaction; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.

This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in this release, organic revenue growth excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted net income and adjusted earnings per diluted share exclude restructuring and restructuring related costs, deal amortization expenses, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation, integration and transaction costs, gains and losses on dispositions, certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. Free cash flow before restructuring and restructuring

A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not provide a quantitative reconciliation of its forward-looking organic revenue growth guidance by business unit to the comparable GAAP measure because forecasting the impact of foreign currency fluctuations by business unit is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. Additionally, the Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow before restructuring and restructuring related costs guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs and impairment charges, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.


Haemonetics Corporation Financial Summary
Condensed Consolidated Statements of Income for the Second Quarter of FY22 and FY21
(Data in thousands, except per share data)

		10/2/2021			9/26/2020			% Inc/(Dec)
								vs Prior Year
		(unaudited)
Net revenues		$	239,897		$	209,486		14.5%
Gross profit		122,541			105,744			15.9%

	R&D	10,853			6,763			60.5%
	S,G&A	75,778			63,570			19.2%
	Amortization of intangible assets	11,400			8,127			40.3%
	Gain on divestitures and sale of assets	—			(31,498)			n/m
Operating expenses		98,031			46,962			108.7%

Operating income		24,510			58,782			(58.3)%

Interest and other expense, net		(4,588)			(3,826)			19.9%
Income before taxes		19,922			54,956			(63.7)%

Tax expense		5,066			6,855			(26.1)%

Net income		$	14,856		$	48,101		(69.1)%


Net income per common share assuming dilution		$	0.29		$	0.94		(69.1)%

Weighted average number of shares:
	Basic	51,039			50,696
	Diluted	51,458			51,093

Profit Margins:								Inc/(Dec) vs prior year profit margin %
Gross profit		51.1		%	50.5		%	0.6%
R&D		4.5		%	3.2		%	1.3%
S,G&A		31.6		%	30.3		%	1.3%
Operating income		10.2		%	28.1		%	(17.9)%
Income before taxes		8.3		%	26.2		%	(17.9)%
Net income		6.2		%	23.0		%	(16.8)%


Haemonetics Corporation Financial Summary
Condensed Consolidated Statements of Income for the Year-to-Date FY22 and FY21
(Data in thousands, except per share data)

		10/2/2021			9/26/2020			% Inc/(Dec)
								vs Prior Year
		(unaudited)
Net revenues		$	468,425		$	405,063		15.6%
Gross profit		230,626			195,774			17.8%

	R&D	23,554			14,513			62.3%
	S,G&A	166,996			125,863			32.7%
	Amortization of intangible assets	23,779			16,399			45.0%
	Gain on divestitures and sale of assets	(9,603)			(31,498)			n/m
Operating expenses		204,726			125,277			63.4%

Operating income		25,900			70,497			(63.3)%

Interest and other expense, net		(8,986)			(7,561)			18.8%
Income before taxes		16,914			62,936			(73.1)%

Tax expense		6,512			4,308			51.2%

Net income		$	10,402		$	58,628		(82.3)%


Net income per common share assuming dilution		$	0.20		$	1.15		(82.6)%

Weighted average number of shares:
	Basic	50,989			50,557
	Diluted	51,358			51,170

Profit Margins:								Inc/(Dec) vs prior year profit margin %
Gross profit		49.2		%	48.3		%	0.9%
R&D		5.0		%	3.6		%	1.4%
S,G&A		35.7		%	31.1		%	4.7%
Operating income		5.5		%	17.4		%	(11.9)%
Income before taxes		3.6		%	15.5		%	(11.9)%
Net income		2.2		%	14.5		%	(12.3)%


Revenue Analysis for the Second Quarter of FY22 and FY21
(Data in thousands)

		Three Months Ended
		10/2/2021		9/26/2020		Reported growth		Currency impact		Acquisition and Divestitures(1)		Other Strategic Exits(2)		Organic growth
		(unaudited)
Revenues by business unit
	Plasma	$	81,940	$	78,408	4.5	%	0.3	%	—	%	(2.6)	%	6.8	%
	Blood Center	76,742		74,913		2.4	%	1.7	%	(0.9)	%	—	%	1.6	%
	Hospital(3)	76,307		50,978		49.7	%	0.9	%	38.4	%	—	%	10.4	%
Net business unit revenues		$	234,989	$	204,299	15.0	%	1.0	%	8.8	%	(0.6)	%	5.8	%
	Service	4,908		5,187		(5.4)	%	1.9	%	—	%	—	%	(7.3)	%
Total net revenues		$	239,897	$	209,486	14.5	%	1.0	%	9.0	%	(0.9)	%	5.4	%
(1) Reflects the impact in Blood Center resulting from the divestiture of Inlog Holdings France SAS (“InLog”). Also reflects the impacts in Hospital of 40.5% related to the acquisition of Vascular Closure from Cardiva Medical Inc. and of (2.1%) related to the divestiture of InLog. (2) Reflects adjustments to both fiscal 2022 and 2021 Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Hospital revenue includes Hemostasis Management revenue of $31.5 million and $26.0 million for the three months ended October 2, 2021 and September 26, 2020, respectively. Hemostasis Management revenue increased 21.0% in the second quarter of fiscal 2022 as compared with the same period of fiscal 2021. Hemostasis Management revenue increased 21.1%, on an organic basis, in the second quarter of fiscal 2022 as compared with the same period of fiscal 2021. Hospital revenue also includes Vascular Closure revenue of $20.8 million for the three months ended October 2, 2021. Vascular Closure revenue is excluded on an organic growth basis.


Revenue Analysis for the Year-to-Date FY22 and FY21
(Data in thousands)

		Six Months Ended
		10/2/2021		9/26/2020		Reported growth		Currency impact		Acquisition and Divestitures(1)		Other Strategic Exits(2)		Organic growth
		(unaudited)
Revenues by business unit
	Plasma	$	153,784	$	146,619	4.9	%	0.6	%	—	%	(2.2)	%	6.5	%
	Blood Center	149,687		152,702		(2.0)	%	2.6	%	(2.4)	%	—	%	(2.2)	%
	Hospital(3)	154,801		95,817		61.6	%	2.7	%	41.0	%	—	%	17.9	%
Net business unit revenues		$	458,272	$	395,138	16.0	%	1.9	%	8.8	%	(0.6)	%	5.9	%
	Service	10,153		9,925		2.3	%	4.3	%	—	%	—	%	(2.0)	%
Total net revenues		$	468,425	$	405,063	15.6	%	1.9	%	8.7	%	(0.7)	%	5.7	%
(1) Reflects the impacts in Blood Center of (1.5%) and (0.9%) related to the divestitures of the Company’s U.S. blood donor management software solutions assets and of Inlog, respectively. Also reflects the impacts in Hospital of 41.3% related to the acquisition of Vascular Closure from Cardiva Medical Inc. and of (0.3%) related to the divestiture of InLog. (2) Reflects adjustments to both fiscal 2022 and 2021 Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Hospital revenue includes Hemostasis Management revenue of $63.7 million and $50.0 million for the six months ended October 2, 2021 and September 26, 2020, respectively. Hemostasis Management revenue increased 27.4% in the first six months of fiscal 2022 as compared with the same period of fiscal 2021. Hemostasis Management revenue increased 25.9%, on an organic basis, in the first six months of fiscal 2022 as compared with the same period of fiscal 2021. Hospital revenue also includes Vascular Closure revenue of $42.6 million for the six months ended October 2, 2021. Vascular Closure revenue is excluded on an organic growth basis.


Condensed Consolidated Balance Sheets
(Data in thousands)

			As of
			10/2/2021		4/3/2021
			(unaudited)
Assets
Cash and cash equivalents			$	192,420	$	192,305
Accounts receivable, net			141,305		127,555
Inventories, net			322,661		322,614
Other current assets			42,860		51,072
		Total current assets	699,246		693,546
Property, plant & equipment, net			223,747		217,559
Intangible assets, net			337,249		365,483
Goodwill			468,590		466,444
Other assets			72,665		76,891
	Total assets		$	1,801,497	$	1,819,923

Liabilities & Stockholders' Equity
Short-term debt & current maturities			$	82,733	$	17,016
Other current liabilities			205,737		236,479
		Total current liabilities	288,470		253,495
Long-term debt			698,043		690,592
Other long-term liabilities			116,435		144,166
Stockholders' equity			698,549		731,670
	Total liabilities & stockholders' equity		$	1,801,497	$	1,819,923


Condensed Consolidated Statements of Cash Flows
(Data in thousands)

	Six Months Ended
	10/2/2021		9/26/2020
	(unaudited)
Cash Flows from Operating Activities:
Net income	$	10,402	$	58,628
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	48,567		41,603
Contingent consideration expense	9,345		—
Share-based compensation expense	12,807		12,119
Amortization of fair value inventory step-up	5,295		—
Impairment of assets	5,144		1,028
Amortization of deferred finance costs	1,813		286
Deferred tax benefit	898		(3,031)
Provision for losses on inventory	114		1,057
Gains on divestitures and sale of assets	(9,603)		(31,498)
Change in other non-cash operating activities	861		76
Change in accounts receivable, net	(14,574)		22,391
Change in inventories, net	(5,475)		(38,189)
Change in other working capital	(23,814)		(23,503)
Net cash provided by operating activities	41,780		40,967
Cash Flows from Investing Activities:
Capital expenditures	(34,731)		(16,035)
Acquisition	(2,500)		(16,606)
Proceeds from divestitures	—		44,978
Proceeds from sale of property, plant and equipment	860		902
Net cash (used in) provided by investing activities	(36,371)		13,239
Cash Flows from Financing Activities:
Borrowings, net of repayments	(8,750)		81,250

Proceeds from employee stock programs	3,779		3,403
Other	22		(20)
Net cash (used in) provided by financing activities	(4,949)		84,633
Effect of exchange rates on cash and cash equivalents	(345)		3,019
Net Change in Cash and Cash Equivalents	115		141,858
Cash and Cash Equivalents at Beginning of the Period	192,305		137,311
Cash and Cash Equivalents at End of Period	$	192,420	$	279,169

Free Cash Flow Reconciliation:
Cash provided by operating activities	$	41,780	$	40,967
Capital expenditures, net of proceeds from sale of property, plant and equipment	(33,871)		(15,133)
Free cash flow after restructuring and restructuring related costs	7,909		25,834
Restructuring and restructuring related costs	29,399		15,791
Tax benefit on restructuring and restructuring related costs	(6,139)		(3,422)
Free cash flow before restructuring and restructuring related costs	$	31,169	$	38,203


Reconciliation of Adjusted Measures for the Second Quarter of FY22 and FY21
(Data in thousands except per share data)
	Three Months Ended
	10/2/2021		9/26/2020
	(unaudited)
GAAP gross profit	$	122,541	$	105,744
Restructuring and restructuring related costs	3,430		3,277
Impairment of assets and PCS2 related charges	185		309
Adjusted gross profit	$	126,156	$	109,330

GAAP operating expenses	$	98,031	$	46,962
Deal amortization	(11,400)		(8,136)
Integration and transaction costs	(625)		(1,773)
MDR and IVDR costs(1)	(2,347)		(736)
Restructuring and restructuring related costs	(1,083)		(1,163)
Litigation-related charges	(145)		—
Impairment of assets and PCS2 related charges	(65)		(267)
Gain on divestitures and sale of assets	—		31,498
Adjusted operating expenses	$	82,366	$	66,385

GAAP operating income	$	24,510	$	58,782
Deal amortization	11,400		8,136
Integration and transaction costs	625		1,773
Restructuring and restructuring related costs	4,513		4,440
Impairment of assets and PCS2 related charges	250		576
MDR and IVDR costs(1)	2,347		736
Litigation-related charges	145		—
Gain on divestitures and sale of assets	—		(31,498)
Adjusted operating income	$	43,790	$	42,945

GAAP net income	$	14,856	$	48,101
Deal amortization	11,400		8,136
Integration and transaction costs	625		1,773
Restructuring and restructuring related costs	4,513		4,440
Impairment of assets and PCS2 related charges	250		576
MDR and IVDR costs(1)	2,347		736
Litigation-related charges	145		—
Gain on divestitures and sale of assets	—		(31,498)
Tax impact associated with adjustments	(3,437)		(636)
Adjusted net income	$	30,699	$	31,628

GAAP net income per common share	$	0.29	$	0.94
Adjusted items after tax per common share assuming dilution	0.31		(0.32)
Adjusted net income per common share assuming dilution	$	0.60	$	0.62

(1)Refers to the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) costs.


Reconciliation of Adjusted Measures for Year-to-Date FY22 and FY21
(Data in thousands except per share data)
	Six Months Ended
	10/2/2021		9/26/2020
	(unaudited)
GAAP gross profit	$	230,626	$	195,774
Restructuring and restructuring related costs	11,512		4,484
Integration and transaction costs	5,295		90
Impairment of assets and PCS2 related charges	3,715		1,232
Adjusted gross profit	$	251,148	$	201,580

GAAP operating expenses	$	204,726	$	125,277
Deal amortization	(23,779)		(16,399)
Integration and transaction costs	(12,063)		(2,973)
MDR and IVDR costs(1)	(4,718)		(1,489)
Restructuring and restructuring related costs	(3,056)		(3,956)
Litigation-related charges	(1,083)		—
Impairment of assets and PCS2 related charges	(178)		(1,850)
Gain on divestitures and sale of assets	9,603		31,498
Adjusted operating expenses	$	169,452	$	130,108

GAAP operating income	$	25,900	$	70,497
Deal amortization	23,779		16,399
Integration and transaction costs	17,358		3,063
Restructuring and restructuring related costs	14,568		8,440
Impairment of assets and PCS2 related charges	3,893		3,082
MDR and IVDR costs(1)	4,718		1,489
Litigation-related charges	1,083		—
Gain on divestitures and sale of assets	(9,603)		(31,498)
Adjusted operating income	$	81,696	$	71,472

GAAP net income	$	10,402	$	58,628
Deal amortization	23,779		16,399
Integration and transaction costs	17,358		3,063
Restructuring and restructuring related costs	14,568		8,440
Impairment of assets and PCS2 related charges	3,893		3,082
MDR and IVDR costs(1)	4,718		1,489
Litigation-related charges	1,083		—
Gain on divestitures and sale of assets	(9,603)		(31,498)
Tax impact associated with adjustments	(10,066)		(4,241)
Adjusted net income	$	56,132	$	55,362

GAAP net income per common share	$	0.20	$	1.15
Adjusted items after tax per common share assuming dilution	0.89		(0.07)
Adjusted net income per common share assuming dilution	$	1.09	$	1.08
(1)Refers to the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) costs.


Projected Fiscal 2022 GAAP and Organic Revenue Growth Rates
			FY 2022
GAAP Revenue Growth			13 - 17%
Currency impact			(1%)
Acquisitions and divestitures(1)			(7-8%)
Other strategic exits(2)			1%
53rd week(3)			1%
Organic Revenue Growth			7 - 10%
(1) Reflects adjustment to fiscal 2021 revenue as a result of the divestiture of the Company’s U.S. blood donor management software solutions assets and Inlog Holdings France SAS, as well as an adjustment to fiscal 2022 revenue related to the acquisition of Cardiva Medical, Inc. (2) Reflects adjustments to Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Reflects adjustment to fiscal 2021 revenue for the impact of the 53rd week.


									Exhibit 99.1

						Investor Contact			Media Contact
						Olga Guyette, Director-Investor Relations			Josh Gitelson, Director-Communications
						(781) 356-9763			(781) 356-9776
						olga.guyette@haemonetics.com			josh.gitelson@haemonetics.com


($ millions)	2nd Quarter 2022 Reported
Plasma	$81.9	4.5%
Hospital	$76.3	49.7%
Blood Center	$76.8	2.4%
Net business unit revenue	$235.0	15.0%
Service	$4.9	(5.4%)
Total net revenue	$239.9	14.5%


			2nd Quarter 2022 Organic
Plasma			6.8%
Hospital			10.4%
Blood Center			1.6%
Net business unit revenue			5.8%
Service			(7.3%)
Total net revenue			5.4%